ZA201307914B - Compositions and methods for inhibiting gene expression of hepatitis b virus - Google Patents
Compositions and methods for inhibiting gene expression of hepatitis b virusInfo
- Publication number
- ZA201307914B ZA201307914B ZA2013/07914A ZA201307914A ZA201307914B ZA 201307914 B ZA201307914 B ZA 201307914B ZA 2013/07914 A ZA2013/07914 A ZA 2013/07914A ZA 201307914 A ZA201307914 A ZA 201307914A ZA 201307914 B ZA201307914 B ZA 201307914B
- Authority
- ZA
- South Africa
- Prior art keywords
- hepatitis
- virus
- compositions
- methods
- gene expression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11172235 | 2011-06-30 | ||
| US13/535,454 US8809293B2 (en) | 2011-06-30 | 2012-06-28 | Compositions and methods for inhibiting gene expression of hepatitis B virus |
| PCT/US2012/044505 WO2013003520A1 (en) | 2011-06-30 | 2012-06-28 | Compositions and methods for inhibiting gene expression of hepatitis b virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201307914B true ZA201307914B (en) | 2015-01-28 |
Family
ID=47391267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2013/07914A ZA201307914B (en) | 2011-06-30 | 2013-10-23 | Compositions and methods for inhibiting gene expression of hepatitis b virus |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8809293B2 (enExample) |
| EP (3) | EP3901263A1 (enExample) |
| JP (5) | JP6165723B2 (enExample) |
| KR (5) | KR102025295B1 (enExample) |
| CN (3) | CN103635576B (enExample) |
| AU (5) | AU2012275355B2 (enExample) |
| BR (1) | BR112013031021A2 (enExample) |
| CA (2) | CA3064103C (enExample) |
| DK (1) | DK2726613T3 (enExample) |
| EA (4) | EA202090994A1 (enExample) |
| ES (1) | ES2690538T3 (enExample) |
| HR (1) | HRP20181564T1 (enExample) |
| IL (3) | IL230226B (enExample) |
| MX (2) | MX342731B (enExample) |
| PL (1) | PL2726613T3 (enExample) |
| PT (1) | PT2726613T (enExample) |
| SG (1) | SG194751A1 (enExample) |
| SI (1) | SI2726613T1 (enExample) |
| TW (5) | TWI695066B (enExample) |
| WO (1) | WO2013003520A1 (enExample) |
| ZA (1) | ZA201307914B (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3587574B1 (en) | 2010-08-17 | 2022-03-16 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
| SG10201604074TA (en) | 2011-04-21 | 2016-07-28 | Isis Pharmaceuticals Inc | Modulation of hepatitis b virus (hbv) expression |
| TWI695066B (zh) | 2011-06-30 | 2020-06-01 | 美商艾羅海德製藥公司 | 用於抑制b型肝炎病毒基因表現之組合物及方法 |
| IN2015DN01087A (enExample) | 2012-08-30 | 2015-06-26 | Replicor Inc | |
| BR112015010116A2 (pt) | 2012-11-15 | 2017-08-22 | Roche Innovation Ct Copenhagen As | COMPOSTOS CONJUGADOS ANTI-SENTIDO ANTI-ApoB |
| HK1215718A1 (zh) | 2013-01-30 | 2016-09-09 | F. Hoffmann-La Roche Ag | Lna寡核苷酸碳水化合物缀合物 |
| US10227588B2 (en) | 2013-10-04 | 2019-03-12 | Novartis Ag | 3′end caps for RNAi agents for use in RNA interference |
| CN105792832B (zh) * | 2013-10-04 | 2021-03-23 | 诺华股份有限公司 | 用于治疗乙肝病毒的有机化合物 |
| EP3052627B1 (en) | 2013-10-04 | 2018-08-22 | Novartis AG | Novel formats for organic compounds for use in rna interference |
| GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| WO2016011123A1 (en) * | 2014-07-16 | 2016-01-21 | Arrowhead Research Corporation | Organic compositions to treat apoc3-related diseases |
| CA2963271A1 (en) * | 2014-10-02 | 2016-04-07 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis b virus gene expression |
| JOP20200092A1 (ar) * | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| US20180355413A1 (en) * | 2014-12-22 | 2018-12-13 | Anapa Biotech A/S | Dual quenching assay for multiplex detection of target nucleic acids |
| US10898505B2 (en) * | 2015-05-06 | 2021-01-26 | Benitec Biopharma Limited | Reagents for treatment of hepatitis B virus (HBV) infection and use thereof |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| CA2996722A1 (en) * | 2015-07-17 | 2017-01-26 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
| CN108350455A (zh) * | 2015-07-29 | 2018-07-31 | 阿布特斯生物制药公司 | 用于使b型肝炎病毒基因表达沉默的组合物和方法 |
| JO3769B1 (ar) * | 2015-08-07 | 2021-01-31 | Arrowhead Pharmaceuticals Inc | علاج RNAi لعدوى فيروس التهاب الكبد B |
| CN108271387B (zh) * | 2015-08-07 | 2023-06-27 | 箭头药业股份有限公司 | 乙型肝炎病毒感染的RNAi疗法 |
| IL296377A (en) * | 2016-03-07 | 2022-11-01 | Arrowhead Pharmaceuticals Inc | Targeting ligands for therapeutic compounds and uses of same |
| CN108713061B (zh) * | 2016-03-09 | 2022-04-05 | 学校法人东京理科大学 | Rna杂交形成用核酸低聚物 |
| RU2747822C2 (ru) | 2016-03-14 | 2021-05-14 | Ф. Хоффманн-Ля Рош Аг | Олигонуклеотиды для понижения экспрессии pd-l1 |
| KR102358280B1 (ko) * | 2016-05-05 | 2022-02-07 | 베니텍 바이오파마 리미티드 | B형 간염 바이러스(hbv) 감염 처리용 시약 및 그 용도 |
| MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
| JOP20170161A1 (ar) * | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| WO2018053185A1 (en) * | 2016-09-14 | 2018-03-22 | Alios Biopharma, Inc. | Modified oligonucleotides and methods of use |
| CN117402852A (zh) * | 2016-10-14 | 2024-01-16 | 精密生物科学公司 | 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶 |
| JP7113009B2 (ja) | 2016-11-07 | 2022-08-04 | アービュタス バイオファーマ コーポレイション | 置換ピリジノン含有三環式化合物およびそれを使用する方法 |
| CN110177544A (zh) | 2016-11-29 | 2019-08-27 | 普尔泰克健康有限公司 | 用于递送治疗剂的外泌体 |
| EP3601216B1 (en) | 2017-03-21 | 2023-10-25 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection |
| CN110520531A (zh) | 2017-04-05 | 2019-11-29 | 赛伦斯治疗有限责任公司 | 产品和组合物 |
| US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
| KR102720270B1 (ko) | 2017-04-18 | 2024-10-23 | 알닐람 파마슈티칼스 인코포레이티드 | B형 간염 바이러스 (hbv)에 감염된 대상체의 치료 방법 |
| TW202424191A (zh) | 2017-10-16 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子 |
| RS64001B1 (sr) | 2017-10-20 | 2023-03-31 | Dicerna Pharmaceuticals Inc | Metode za lečenje infekcije hepatitisom b |
| HRP20250192T1 (hr) | 2017-12-01 | 2025-04-11 | Suzhou Ribo Life Science Co., Ltd. | Nukleinska kiselina, sastav i konjugat koji je sadrži, te metoda pripreme i uporaba |
| CN110997917B (zh) | 2017-12-01 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110997919B (zh) | 2017-12-01 | 2024-04-02 | 苏州瑞博生物技术股份有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110945130B (zh) | 2017-12-01 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| CN116375774B (zh) | 2017-12-29 | 2025-09-23 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
| MX2020010383A (es) | 2018-04-05 | 2020-12-10 | Hoffmann La Roche | Uso de inhibidores de fubp1 para el tratamiento de infeccion de virus de hepatitis b. |
| US11279929B2 (en) | 2018-07-03 | 2022-03-22 | Hoffmann-La Roche, Inc. | Oligonucleotides for modulating Tau expression |
| CR20210015A (es) | 2018-07-13 | 2021-03-22 | Hoffmann La Roche | Oligonucleótidos para modular la expresión de rtel 1 |
| TWI869058B (zh) | 2018-07-27 | 2025-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 |
| EP3837366A1 (en) | 2018-08-13 | 2021-06-23 | Alnylam Pharmaceuticals, Inc. | Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| CN109385459A (zh) * | 2018-10-18 | 2019-02-26 | 大连理工大学 | 一种细胞分裂素通过抑制dna聚合酶活性抑制细胞增殖的方法 |
| TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| US12496347B2 (en) | 2018-12-28 | 2025-12-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| KR20210130736A (ko) | 2019-02-07 | 2021-11-01 | 애로우헤드 파마슈티컬스 인코포레이티드 | B형 간염 바이러스 감염에 대한 RNAi 작용제 |
| WO2020214974A1 (en) | 2019-04-18 | 2020-10-22 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| TW202103698A (zh) | 2019-04-18 | 2021-02-01 | 美商健生醫藥公司 | 用於治療b型肝炎病毒感染之組合療法 |
| CN113227376B (zh) | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP2022536945A (ja) * | 2019-06-18 | 2022-08-22 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Ｂ型肝炎ウイルス（ＨＢＶ）ワクチンおよびＨＢＶを標的化するＲＮＡｉの組合せ |
| US20220305107A1 (en) * | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi |
| CN110218728A (zh) * | 2019-06-28 | 2019-09-10 | 厦门甘宝利生物医药有限公司 | 一种新化合物及其应用 |
| JP2023506540A (ja) | 2019-12-19 | 2023-02-16 | エフ． ホフマン－ラ ロシュ エージー． | Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用 |
| WO2021122910A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of sbds inhibitors for treating hepatitis b virus infection |
| EP4077670A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of cops3 inhibitors for treating hepatitis b virus infection |
| CN114867856A (zh) | 2019-12-19 | 2022-08-05 | 豪夫迈·罗氏有限公司 | Saraf抑制剂用于治疗乙型肝炎病毒感染的用途 |
| EP4077667A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of sept9 inhibitors for treating hepatitis b virus infection |
| US20210285000A1 (en) | 2020-03-05 | 2021-09-16 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| EP4121533A1 (en) * | 2020-03-06 | 2023-01-25 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (sina) molecules and uses thereof |
| WO2022038211A2 (en) | 2020-08-21 | 2022-02-24 | F. Hoffmann-La Roche Ag | Use of a1cf inhibitors for treating hepatitis b virus infection |
| US20240124879A1 (en) * | 2020-12-18 | 2024-04-18 | Olix Pharmaceuticals, Inc. | Rnai agent for inhibiting hbv expression and use thereof |
| WO2022133230A1 (en) | 2020-12-18 | 2022-06-23 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| US20240299557A1 (en) * | 2021-01-22 | 2024-09-12 | Taibidi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Compound for degrading deoxyribonucleic acid (dna) polymerase, and use thereof |
| TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| CA3240651A1 (en) * | 2021-12-16 | 2023-06-22 | Yunfei Li | Dsrna, preparation method therefor and use thereof |
| EP4448106A1 (en) | 2021-12-17 | 2024-10-23 | Hoffmann-La Roche Inc. | Combination of oligonucleotides for modulating rtel1 and fubp1 |
| WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
| CN119452087A (zh) * | 2022-06-21 | 2025-02-14 | 正大天晴药业集团股份有限公司 | 用于抑制乙型肝炎病毒的双链核糖核酸 |
| TW202430183A (zh) * | 2022-12-16 | 2024-08-01 | 大陸商上海拓界生物醫藥科技有限公司 | Ｔｏｌｌ樣受體調節劑與ｄｓＲＮＡ的聯合治療 |
| CN119331868A (zh) * | 2023-07-18 | 2025-01-21 | 复旦大学 | 一种核酸、含有该核酸的药物组合物和缀合物及其应用 |
| CN119913146A (zh) * | 2023-09-28 | 2025-05-02 | 北京凯因科技股份有限公司 | 用于抑制乙型肝炎病毒的siRNA及其用途 |
| CN119799705B (zh) * | 2024-07-08 | 2025-12-12 | 杭州天龙药业有限公司 | 靶向调控HBV基因表达的siRNA及其应用 |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| CA1340032C (en) | 1987-06-24 | 1998-09-08 | Jim Haralambidis | Lucleoside derivatives |
| US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
| US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
| US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
| DE69034150T2 (de) | 1989-10-24 | 2005-08-25 | Isis Pharmaceuticals, Inc., Carlsbad | 2'-Modifizierte Oligonukleotide |
| US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
| EP0800830A3 (en) | 1989-11-03 | 1999-03-17 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
| US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
| US5506351A (en) | 1992-07-23 | 1996-04-09 | Isis Pharmaceuticals | Process for the preparation of 2'-O-alkyl guanosine and related compounds |
| US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
| US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
| US5212295A (en) | 1990-01-11 | 1993-05-18 | Isis Pharmaceuticals | Monomers for preparation of oligonucleotides having chiral phosphorus linkages |
| US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
| US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
| US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
| US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| US6262241B1 (en) | 1990-08-13 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Compound for detecting and modulating RNA activity and gene expression |
| US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| JP2823959B2 (ja) | 1991-10-24 | 1998-11-11 | アイシス・ファーマシューティカルス・インコーポレーテッド | 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド |
| US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
| US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| US20030206887A1 (en) | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
| GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
| HU9501974D0 (en) | 1993-03-31 | 1995-09-28 | Sterling Winthrop Inc | Oligonucleotides with amide linkages replacing phosphodiester linkages |
| US5571902A (en) | 1993-07-29 | 1996-11-05 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| US5554746A (en) | 1994-05-16 | 1996-09-10 | Isis Pharmaceuticals, Inc. | Lactam nucleic acids |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| US5856459A (en) * | 1995-06-06 | 1999-01-05 | Hybridon, Inc. | Oligonucleotides specific for hepatitis B virus |
| US5985662A (en) * | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
| US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
| US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
| CN1057302C (zh) * | 1997-08-27 | 2000-10-11 | 中国科学院上海生物化学研究所 | 抑制乙型肝炎病毒复制的反义脱氧寡核苷酸 |
| US6271358B1 (en) | 1998-07-27 | 2001-08-07 | Isis Pharmaceuticals, Inc. | RNA targeted 2′-modified oligonucleotides that are conformationally preorganized |
| BR9914772A (pt) | 1998-10-09 | 2001-12-11 | Ingene Inc | Conjunto de elementos genéticos, vetor, célulahospedeira, conjunto para a produção de umasequência de ácido nucléico, método para aprodução in vivo ou in vitro de uma sequência deácido nucléico, transcrição de cdna, molécula deácido nucléico inibidor, transcrição de mrna,molécula heteroduplex e composiçãofarmacêutica |
| US5977341A (en) | 1998-11-20 | 1999-11-02 | Isis Pharmaceuticals Inc. | Antisense modulation of inhibitor-kappa B kinase-beta expression |
| US20050032733A1 (en) * | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
| US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US8273866B2 (en) | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| WO2003070918A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| EP1383782A1 (en) | 2001-03-26 | 2004-01-28 | Sirna Therpeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| CA2526831C (en) * | 2001-05-18 | 2012-07-31 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
| US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| US10590418B2 (en) | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
| US20030198627A1 (en) | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
| US6635428B2 (en) | 2001-12-04 | 2003-10-21 | Quest Diagnostics Investments Incorporated | Oligonucleotides and methods for detecting hepatitis B viral nucleic acids |
| EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US8232383B2 (en) | 2002-02-20 | 2012-07-31 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| KR101201664B1 (ko) | 2002-08-05 | 2012-11-15 | 사일런스 테라퓨틱스 아게 | 신규한 형태의 간섭 ｒｎａ 분자 |
| US7956176B2 (en) | 2002-09-05 | 2011-06-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
| WO2005009346A2 (en) | 2003-06-24 | 2005-02-03 | Mirus Corporation | Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo |
| EP1709178A4 (en) * | 2003-12-16 | 2008-01-09 | Agency Science Tech & Res | METHODS AND COMPOUNDS FOR MODIFYING MICROBIAL CONTAMINATION DEGREE OF HEPATITIS VIRUS |
| AU2005203822A1 (en) | 2004-01-12 | 2005-07-21 | Lorus Therapeutics Inc. | Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in combination therapies for the treatment of cancer |
| AU2005248147A1 (en) | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| ATE518954T1 (de) | 2004-08-18 | 2011-08-15 | Lorus Therapeutics Inc | Kleine interferierende rna-moleküle gegen ribonukleotidreduktase und ihre verwendungen |
| KR20100060018A (ko) * | 2005-03-09 | 2010-06-04 | 재단법인 목암생명공학연구소 | 작은 간섭 ｒｎａ 및 이를 포함하는 ｂ형 간염 바이러스 치료용 약학 조성물 |
| RU2418068C2 (ru) * | 2005-08-17 | 2011-05-10 | Сирна Терапьютикс, Инк. | Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк |
| AU2006279454B2 (en) | 2005-08-17 | 2011-12-15 | Sirna Therapeutics, Inc. | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
| CN101426912A (zh) * | 2005-08-17 | 2009-05-06 | 瑟纳治疗公司 | 介导rna干扰的化学修饰短干扰核酸分子 |
| KR20080086440A (ko) | 2005-11-01 | 2008-09-25 | 알닐람 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 ＲＮＡｉ 억제 |
| WO2008131419A2 (en) | 2007-04-23 | 2008-10-30 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of rna interference agents |
| WO2008146251A2 (en) * | 2007-05-29 | 2008-12-04 | University Of The Witwatersrand, Johannesburg | A primary micro rna expression cassette |
| KR20100069679A (ko) * | 2007-09-17 | 2010-06-24 | 재단법인 목암생명공학연구소 | ＨＢＶ 또는 ＨＣＶ의 유전자 발현을 하향 조절하는 ｓｉＲＮＡ의 혈청 안정성 향상 및 면역 반응 저감 방법 |
| US20090247608A1 (en) | 2007-12-04 | 2009-10-01 | Alnylam Pharmaceuticals, Inc. | Targeting Lipids |
| US8207138B2 (en) | 2009-05-19 | 2012-06-26 | Medtronic, Inc. | Methods and devices for improved efficiency of RNA delivery to cells |
| CN102481367B (zh) | 2009-07-06 | 2015-04-29 | 弗·哈夫曼-拉罗切有限公司 | 结合地高辛配基的双特异性抗体 |
| US20110152349A1 (en) * | 2009-12-18 | 2011-06-23 | Anke Geick | Compositions and methods for inhibiting expression of il-18 genes |
| US9198972B2 (en) | 2010-01-28 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
| EP2390327A1 (en) | 2010-05-27 | 2011-11-30 | Sylentis S.A. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| EP3587574B1 (en) | 2010-08-17 | 2022-03-16 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
| CA2812046A1 (en) | 2010-09-15 | 2012-03-22 | Alnylam Pharmaceuticals, Inc. | Modified irna agents |
| CN101948834B (zh) * | 2010-09-16 | 2012-07-04 | 山东大学 | 用于治疗HBV的siRNA |
| DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| SG10201604074TA (en) | 2011-04-21 | 2016-07-28 | Isis Pharmaceuticals Inc | Modulation of hepatitis b virus (hbv) expression |
| TWI695066B (zh) | 2011-06-30 | 2020-06-01 | 美商艾羅海德製藥公司 | 用於抑制b型肝炎病毒基因表現之組合物及方法 |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| US10266850B2 (en) | 2012-05-25 | 2019-04-23 | The Regents Of The University Of California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| WO2015042447A1 (en) | 2013-09-20 | 2015-03-26 | Isis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
| CN105792832B (zh) | 2013-10-04 | 2021-03-23 | 诺华股份有限公司 | 用于治疗乙肝病毒的有机化合物 |
| EP3811977B1 (en) | 2014-05-01 | 2025-12-03 | Ionis Pharmaceuticals, Inc. | Method for synthesis of reactive conjugate clusters |
| JOP20200115A1 (ar) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) |
| JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| CA2996722A1 (en) | 2015-07-17 | 2017-01-26 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
| CN108350455A (zh) | 2015-07-29 | 2018-07-31 | 阿布特斯生物制药公司 | 用于使b型肝炎病毒基因表达沉默的组合物和方法 |
| CN108271387B (zh) | 2015-08-07 | 2023-06-27 | 箭头药业股份有限公司 | 乙型肝炎病毒感染的RNAi疗法 |
| MA45478A (fr) | 2016-04-11 | 2019-02-20 | Arbutus Biopharma Corp | Compositions de conjugués d'acides nucléiques ciblés |
| JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| CN116942841A (zh) | 2016-09-02 | 2023-10-27 | 箭头药业股份有限公司 | 靶向配体 |
-
2012
- 2012-06-28 TW TW106137891A patent/TWI695066B/zh active
- 2012-06-28 TW TW101123338A patent/TWI659040B/zh active
- 2012-06-28 ES ES12804876.6T patent/ES2690538T3/es active Active
- 2012-06-28 CN CN201280031939.3A patent/CN103635576B/zh active Active
- 2012-06-28 PL PL12804876T patent/PL2726613T3/pl unknown
- 2012-06-28 HR HRP20181564TT patent/HRP20181564T1/hr unknown
- 2012-06-28 KR KR1020137031029A patent/KR102025295B1/ko active Active
- 2012-06-28 SG SG2013081286A patent/SG194751A1/en unknown
- 2012-06-28 MX MX2013013556A patent/MX342731B/es active IP Right Grant
- 2012-06-28 PT PT12804876T patent/PT2726613T/pt unknown
- 2012-06-28 TW TW111126981A patent/TW202244278A/zh unknown
- 2012-06-28 EA EA202090994A patent/EA202090994A1/ru unknown
- 2012-06-28 EA EA202191537A patent/EA202191537A1/ru unknown
- 2012-06-28 CA CA3064103A patent/CA3064103C/en active Active
- 2012-06-28 CN CN202110547168.4A patent/CN113430196B/zh active Active
- 2012-06-28 JP JP2014518986A patent/JP6165723B2/ja active Active
- 2012-06-28 EP EP21166938.7A patent/EP3901263A1/en active Pending
- 2012-06-28 US US13/535,454 patent/US8809293B2/en not_active Ceased
- 2012-06-28 EP EP12804876.6A patent/EP2726613B1/en active Active
- 2012-06-28 TW TW109115575A patent/TWI786401B/zh active
- 2012-06-28 TW TW113106985A patent/TW202424196A/zh unknown
- 2012-06-28 AU AU2012275355A patent/AU2012275355B2/en not_active Ceased
- 2012-06-28 KR KR1020227028219A patent/KR102554783B1/ko active Active
- 2012-06-28 CA CA2833778A patent/CA2833778C/en active Active
- 2012-06-28 DK DK12804876.6T patent/DK2726613T3/en active
- 2012-06-28 EA EA201690497A patent/EA035756B1/ru unknown
- 2012-06-28 KR KR1020197027444A patent/KR102167524B1/ko active Active
- 2012-06-28 WO PCT/US2012/044505 patent/WO2013003520A1/en not_active Ceased
- 2012-06-28 EA EA201391394A patent/EA024762B9/ru not_active IP Right Cessation
- 2012-06-28 CN CN201610903171.4A patent/CN106434665B/zh active Active
- 2012-06-28 KR KR1020207029321A patent/KR102434346B1/ko active Active
- 2012-06-28 SI SI201231383T patent/SI2726613T1/sl unknown
- 2012-06-28 KR KR1020217028122A patent/KR102434357B1/ko active Active
- 2012-06-28 BR BR112013031021-9A patent/BR112013031021A2/pt not_active Application Discontinuation
- 2012-06-28 EP EP18187709.3A patent/EP3418386B1/en active Active
-
2013
- 2013-10-23 ZA ZA2013/07914A patent/ZA201307914B/en unknown
- 2013-11-20 MX MX2020011807A patent/MX2020011807A/es unknown
- 2013-12-29 IL IL230226A patent/IL230226B/en active IP Right Grant
-
2016
- 2016-08-19 US US15/241,733 patent/USRE48345E1/en active Active
-
2017
- 2017-04-03 JP JP2017073870A patent/JP2017169568A/ja not_active Withdrawn
- 2017-08-03 AU AU2017210563A patent/AU2017210563B2/en not_active Ceased
-
2019
- 2019-04-17 JP JP2019078663A patent/JP6959293B2/ja active Active
- 2019-10-02 AU AU2019240625A patent/AU2019240625B2/en not_active Ceased
- 2019-11-24 IL IL270877A patent/IL270877B/en unknown
-
2021
- 2021-07-04 IL IL284578A patent/IL284578A/en unknown
- 2021-08-10 JP JP2021130741A patent/JP2021191274A/ja active Pending
-
2022
- 2022-04-08 AU AU2022202365A patent/AU2022202365A1/en not_active Abandoned
- 2022-07-20 AU AU2022206748A patent/AU2022206748A1/en not_active Abandoned
-
2023
- 2023-09-19 JP JP2023150873A patent/JP2023179497A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201307914B (en) | Compositions and methods for inhibiting gene expression of hepatitis b virus | |
| IL269662A (en) | Hepatitis C virus inhibitors | |
| IL265410B (en) | Preparations and methods for inhibiting expression of the alas1 gene | |
| PH12013501969A1 (en) | Compositions and methods for inhibiting expression of tmprss6 gene | |
| SG11201402609RA (en) | Compositions and methods for treating hepatitis c virus | |
| IL224369B (en) | Combinations of inhibitors for hepatitis c virus | |
| ZA201303752B (en) | Inhibitors of hepatitis c virus | |
| PL2739293T3 (pl) | Sposoby i kompozycje wytwarzania wirusa krowianki | |
| ZA201306720B (en) | Hepatitis c virus inhibitors | |
| IL229270B (en) | Hepatitis c virus inhibitors | |
| EP2768517A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| ZA201309356B (en) | Hepatitis c virus inhibitors | |
| EP2651906A4 (en) | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | |
| AP2014007650A0 (en) | Inhibition of viral gene expression | |
| ZA201308011B (en) | Processes for preparing inhibitors of the hepatitis c virus | |
| IL232889A0 (en) | Compounds and methods for treating hepatitis c virus | |
| HK1194287A (en) | Compositions and methods for inhibiting expression of tmprss6 gene |